AU2020346695A1 - Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof - Google Patents

Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof Download PDF

Info

Publication number
AU2020346695A1
AU2020346695A1 AU2020346695A AU2020346695A AU2020346695A1 AU 2020346695 A1 AU2020346695 A1 AU 2020346695A1 AU 2020346695 A AU2020346695 A AU 2020346695A AU 2020346695 A AU2020346695 A AU 2020346695A AU 2020346695 A1 AU2020346695 A1 AU 2020346695A1
Authority
AU
Australia
Prior art keywords
cytisine
subject
administration
vaping
smoking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020346695A
Other languages
English (en)
Inventor
Daniel F. Cain
Anthony Clarke
Cindy A. Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achieve Life Sciences Inc
Original Assignee
Achieve Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achieve Life Sciences Inc filed Critical Achieve Life Sciences Inc
Publication of AU2020346695A1 publication Critical patent/AU2020346695A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020346695A 2019-09-12 2020-08-14 Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof Pending AU2020346695A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899637P 2019-09-12 2019-09-12
US62/899,637 2019-09-12
US202062988890P 2020-03-12 2020-03-12
US62/988,890 2020-03-12
PCT/US2020/046308 WO2021050203A1 (en) 2019-09-12 2020-08-14 Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Publications (1)

Publication Number Publication Date
AU2020346695A1 true AU2020346695A1 (en) 2022-04-28

Family

ID=74866435

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020346695A Pending AU2020346695A1 (en) 2019-09-12 2020-08-14 Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Country Status (11)

Country Link
US (3) US11083715B2 (https=)
EP (1) EP4027815B1 (https=)
JP (2) JP7742832B2 (https=)
KR (1) KR20220074895A (https=)
CN (4) CN119587493A (https=)
AU (1) AU2020346695A1 (https=)
BR (1) BR112022004519A2 (https=)
CA (1) CA3153405A1 (https=)
MX (1) MX2022002882A (https=)
WO (1) WO2021050203A1 (https=)
ZA (1) ZA202204075B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3153405A1 (en) * 2019-09-12 2021-03-18 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
EP4399517A4 (en) * 2021-09-08 2025-10-15 Achieve Life Sciences Inc ANALYTICAL METHODS FOR EVALUATING THE PURITY OF CYTISINE
JP2024095092A (ja) * 2022-12-28 2024-07-10 株式会社日立製作所 生成装置、生成方法、および生成プログラム
WO2024226736A2 (en) * 2023-04-26 2024-10-31 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125699B (en) 1982-02-22 1986-02-12 Bruss Ni Sanitarno Gigieniches Medicinal preparation having antinicotine effect and method for obtention thereof
WO1998018798A1 (en) * 1996-10-30 1998-05-07 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
CN104906669A (zh) * 2007-03-30 2015-09-16 菲利普莫里斯生产公司 用于输送药剂的装置和方法
CN103284319A (zh) * 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
WO2014205449A2 (en) * 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
JP6324964B2 (ja) 2013-08-23 2018-05-16 久光製薬株式会社 貼付剤
PL409829A1 (pl) * 2014-10-18 2016-04-25 Łukasz Zalewski Płyn z cytyzyną do elektronicznych papierosów
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
EP3658561A1 (en) * 2017-07-24 2020-06-03 Achieve Pharma UK Limited Cytisine salts
CA3153405A1 (en) * 2019-09-12 2021-03-18 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Also Published As

Publication number Publication date
EP4027815A4 (en) 2023-06-07
WO2021050203A1 (en) 2021-03-18
KR20220074895A (ko) 2022-06-03
JP2022548876A (ja) 2022-11-22
EP4027815A1 (en) 2022-07-20
CN114727647A (zh) 2022-07-08
US20210330652A1 (en) 2021-10-28
CN118286217A (zh) 2024-07-05
US20210077475A1 (en) 2021-03-18
EP4027815B1 (en) 2026-04-15
CN119564619A (zh) 2025-03-07
US20210077473A1 (en) 2021-03-18
CN119587493A (zh) 2025-03-11
MX2022002882A (es) 2022-05-10
US11083715B2 (en) 2021-08-10
JP7742832B2 (ja) 2025-09-22
CA3153405A1 (en) 2021-03-18
ZA202204075B (en) 2023-11-29
JP2025081331A (ja) 2025-05-27
US11083716B2 (en) 2021-08-10
BR112022004519A2 (pt) 2022-05-31

Similar Documents

Publication Publication Date Title
US11083716B2 (en) Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
US20250302808A1 (en) Dexmedetomidine treatment regimens
US20120225949A1 (en) Compositions and methods for treating bipolar disorder
WO2011020061A2 (en) Compositions and methods of for treating bipolar disorder
Upadhyaya et al. Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study
Hertling et al. Craving and other characteristics of the comorbidity of alcohol and nicotine dependence
Wagen et al. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease
US20220071989A1 (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
Ordak et al. Pharmacotherapy of patients taking new psychoactive substances: a systematic review and analysis of case reports
AU2019395250A1 (en) Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
WO2024226736A2 (en) Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
Harlivasari et al. The role of twice-daily N-acetylcysteine (NAC) 2400 mg in smoking cessation: a randomized, placebo-controlled trial in Indonesia
KR20250040635A (ko) 4-(3-시아노페닐)-6-피리디닐피리미딘 mglu5 음성 알로스테릭 조절인자를 이용해 물질 사용 장애를 치료하는 방법
Farnam Zyban: a new aid to smoking cessation treatment--will it work for psychiatric patients?
Sinclair et al. Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology
Guidance Mental Health Clinician Guidance for Managing People’s Smoking Cessation
WO2025255215A1 (en) Methods and compositions for treating sleep apnea
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
RENNARD et al. 13 Treatment of Stable COPD
Sullivan et al. State of the art reviews: smoking cessation: a review of treatment considerations